Insider Selling: Tyme Technologies Inc (NASDAQ:TYME) Major Shareholder Sells 20,000 Shares of Stock

Tyme Technologies Inc (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $1.14, for a total transaction of $22,800.00. Following the transaction, the insider now owns 26,070,521 shares in the company, valued at $29,720,393.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Michael Demurjian also recently made the following trade(s):

  • On Monday, November 25th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.13, for a total transaction of $22,600.00.
  • On Monday, November 18th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.09, for a total transaction of $21,800.00.
  • On Monday, November 11th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.16, for a total transaction of $23,200.00.
  • On Monday, November 4th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.27, for a total transaction of $25,400.00.
  • On Monday, October 28th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.36, for a total value of $27,200.00.
  • On Monday, October 21st, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.40, for a total value of $28,000.00.
  • On Monday, October 14th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $92.98, for a total value of $1,859,600.00.
  • On Monday, October 7th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.35, for a total transaction of $27,000.00.
  • On Tuesday, October 1st, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.42, for a total transaction of $28,400.00.
  • On Monday, September 23rd, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.67, for a total transaction of $33,400.00.

Tyme Technologies stock traded down $0.01 during trading hours on Tuesday, hitting $1.12. The stock had a trading volume of 226,117 shares, compared to its average volume of 622,971. Tyme Technologies Inc has a 1-year low of $0.92 and a 1-year high of $4.64. The stock has a market capitalization of $126.50 million, a price-to-earnings ratio of -3.50 and a beta of 0.34. The stock’s fifty day moving average is $1.25 and its two-hundred day moving average is $1.25.

Tyme Technologies (NASDAQ:TYME) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.02. On average, research analysts expect that Tyme Technologies Inc will post -0.21 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Morgan Stanley increased its holdings in Tyme Technologies by 187.8% during the 2nd quarter. Morgan Stanley now owns 139,579 shares of the company’s stock valued at $170,000 after acquiring an additional 91,081 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Tyme Technologies by 5.9% in the second quarter. Bank of New York Mellon Corp now owns 306,199 shares of the company’s stock valued at $374,000 after purchasing an additional 17,173 shares in the last quarter. Perkins Capital Management Inc. lifted its holdings in shares of Tyme Technologies by 77.0% in the third quarter. Perkins Capital Management Inc. now owns 142,500 shares of the company’s stock valued at $170,000 after purchasing an additional 62,000 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Tyme Technologies in the third quarter valued at approximately $71,000. Finally, Paloma Partners Management Co purchased a new position in shares of Tyme Technologies during the 2nd quarter worth approximately $238,000. 12.93% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts recently issued reports on TYME shares. Zacks Investment Research raised shares of Tyme Technologies from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a report on Friday, November 8th. HC Wainwright began coverage on shares of Tyme Technologies in a research report on Monday, August 12th. They set a “buy” rating on the stock. Finally, ValuEngine raised shares of Tyme Technologies from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd.

Tyme Technologies Company Profile

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Further Reading: Death Cross

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.